An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

linking the pathogenesis of Crohn’s disease with this inflammation pathway. The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

Crohn's disease and ulcerative colitis look set to ... with results of a head-to-head trial pitting the antibody against Stelara due later this year. "With more than 30 ongoing or planned trials ...

The clearance shores up the competitive position for Omvoh (mirikizumab) in the increasingly competitive inflammatory bowel disease ... In Crohn's, Skyrizi, Stelara, and Ilumya are already ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million ...

So with respect to head-to-head studies, we only have one head-to-head study in Crohn's disease comparing ustekinumab and adalimumab in the SEAVUE study. The SEAVUE study looked at the efficacy ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...